MX353096B - Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. - Google Patents
Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.Info
- Publication number
- MX353096B MX353096B MX2013001917A MX2013001917A MX353096B MX 353096 B MX353096 B MX 353096B MX 2013001917 A MX2013001917 A MX 2013001917A MX 2013001917 A MX2013001917 A MX 2013001917A MX 353096 B MX353096 B MX 353096B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- mci
- cognitive impairment
- miild
- discorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40190710P | 2010-08-19 | 2010-08-19 | |
| PCT/US2011/048472 WO2012024616A1 (en) | 2010-08-19 | 2011-08-19 | Methods of treating miild cognitive impairment (mci) and related discorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013001917A MX2013001917A (es) | 2013-10-25 |
| MX353096B true MX353096B (es) | 2017-12-19 |
Family
ID=45605447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013001917A MX353096B (es) | 2010-08-19 | 2011-08-19 | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10449177B2 (https=) |
| EP (1) | EP2605655B1 (https=) |
| JP (2) | JP6250394B2 (https=) |
| AU (1) | AU2011291506B2 (https=) |
| BR (1) | BR112013003847A8 (https=) |
| CA (1) | CA2808630A1 (https=) |
| DK (1) | DK2605655T3 (https=) |
| ES (1) | ES2705027T3 (https=) |
| MX (1) | MX353096B (https=) |
| WO (1) | WO2012024616A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6250394B2 (ja) | 2010-08-19 | 2017-12-20 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 軽度の認知障害（ｍｃｉ）および関連障害の処置方法 |
| AU2013299656C1 (en) | 2012-08-07 | 2017-06-22 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| US20140371283A1 (en) | 2013-02-12 | 2014-12-18 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| WO2014152207A1 (en) | 2013-03-15 | 2014-09-25 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| CA2941415A1 (en) | 2014-03-21 | 2015-09-24 | Alzheon, Inc. | Methods for treating neurological disorders |
| KR102220260B1 (ko) | 2015-02-18 | 2021-02-25 | 버크 인스티튜트 포 리서치 온 에이징 | 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘 |
| WO2016187339A1 (en) * | 2015-05-18 | 2016-11-24 | Synaptec Development Llc | GALANTAMINE CLEARANCE OF AMYLOIDß |
| FI3347002T3 (fi) | 2015-09-10 | 2023-08-10 | Alzheon Inc | Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa |
| CA3007641C (en) | 2015-12-09 | 2023-10-17 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| US20180250249A1 (en) * | 2016-02-02 | 2018-09-06 | Alzheon, Inc. | Methods of treating neurodegenerative disorders in a particular population |
| IL262957B2 (en) | 2016-05-12 | 2024-04-01 | Buck Inst Res Aging | 6-Fluorotropistrone and a pharmaceutical formulation comprising it for the relief of amyloid-related diseases |
| MX2019007981A (es) | 2017-01-03 | 2019-10-15 | Bioatla Llc | Terapeutica de proteinas para el tratamiento de celulas senescentes. |
| IL312612A (en) | 2018-07-11 | 2024-07-01 | Rubedo Life Sciences Inc | Senolytic compositions and uses thereof |
| CN110232679A (zh) * | 2019-05-24 | 2019-09-13 | 潘丹 | 一种阿尔茨海默症遗传生物标志物确定方法及系统 |
| US12521362B2 (en) | 2019-07-25 | 2026-01-13 | Tokyo University Of Science Foundation | Agent for treating, preventing, or improving psychiatric and nervous system disorders or symptoms |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JPS5936675A (ja) | 1982-07-13 | 1984-02-28 | サンド・アクチエンゲゼルシヤフト | 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド |
| US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
| WO1992013069A1 (en) | 1991-01-21 | 1992-08-06 | Imperial College Of Science, Technology & Medicine | Test and model for alzheimer's disease |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5206264A (en) | 1991-11-04 | 1993-04-27 | Cypros Pharmaceutical Corporation | Use of disulfiram to prevent cardiovascular damage |
| EP0620849B1 (en) | 1992-01-07 | 2003-06-25 | Elan Pharmaceuticals, Inc. | Transgenic animal models for alzheimer's disease |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| US5942400A (en) | 1995-06-07 | 1999-08-24 | Elan Pharmaceuticals, Inc. | Assays for detecting β-secretase |
| SE9600683D0 (sv) | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
| US6045829A (en) | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| CN1300320C (zh) | 1998-09-24 | 2007-02-14 | 法玛西雅厄普约翰美国公司 | 阿尔茨海默氏疾病分泌酶 |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
| EP1175390B1 (en) | 1999-04-05 | 2005-02-02 | Emisphere Technologies, Inc. | Disodium salts, monohydrates, and ethanol solvates |
| US20040092511A1 (en) | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
| US20070059367A1 (en) | 2000-06-06 | 2007-03-15 | Cherukuri S R | Drug Delivery System and Associated Methods |
| US20020115727A1 (en) | 2000-12-04 | 2002-08-22 | Senanayake Chris H. | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines |
| US20020107244A1 (en) | 2001-02-02 | 2002-08-08 | Howard Harry R. | Combination treatment for depression |
| US20040132826A1 (en) | 2002-10-25 | 2004-07-08 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| CA2503381A1 (en) | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| FR2846559B1 (fr) | 2002-10-31 | 2007-06-15 | Centre Nat Rech Scient | Composition pharmaceutique pour la preparation d'un medicament destine a traiter et/ou a prevenir une pathologie liee a une conduite obsessionnelle |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| AU2005235162B2 (en) | 2004-04-21 | 2010-11-18 | Mear Holding B.V. | System for measuring pulsatile vascular resistance |
| WO2005105089A1 (ja) | 2004-04-30 | 2005-11-10 | National University Corporation Chiba University | 精神神経疾患の治療薬 |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| KR20070087678A (ko) | 2004-12-20 | 2007-08-28 | 컬리지움 파마슈티칼, 인코포레이티드 | 수면 장애용 약제 조성물 |
| EP1844000B1 (en) | 2004-12-23 | 2010-01-27 | Xenoport, Inc. | Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
| JP2008537961A (ja) | 2005-04-15 | 2008-10-02 | ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ | Ｇｐｃｒモジュレーター |
| GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
| US20070112017A1 (en) * | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| WO2007099069A1 (en) | 2006-03-01 | 2007-09-07 | Galderma Research & Development | Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof |
| CN102838532A (zh) | 2006-11-24 | 2012-12-26 | Ac免疫有限公司 | 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物 |
| WO2008074896A1 (en) | 2006-12-21 | 2008-06-26 | Prendergast Patrick T | Compositions and methods for treatment of chronic neurological disorders |
| WO2008137420A1 (en) | 2007-05-03 | 2008-11-13 | Emory University | Honokiol analogs and their use in treating cancers |
| CA2705422A1 (en) | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
| CL2007003877A1 (es) | 2007-12-28 | 2008-06-27 | Univ De Concepcion Lab Androma | Composicion farmaceutica que comprende un complejo de inclusion formado por disulfiram y una ciclodextrina; y su uso para el tratamiento de la dependencia de alcohol y cocaina. |
| AU2009241847B2 (en) | 2008-04-28 | 2014-07-10 | Zogenix, Inc. | Novel formulations for treatment of migraine |
| EP2310019A4 (en) | 2008-05-29 | 2011-06-01 | Albany Molecular Res Inc | 5-HT3 RECEPTOR MODULATORS, MANUFACTURING METHOD AND ITS USE |
| CN102159199B (zh) * | 2008-09-25 | 2012-11-21 | 株式会社Bioland | 用于治疗或预防淀粉样蛋白相关疾病的包含4-o-甲基和厚朴酚的组合物 |
| BRPI0914080A2 (pt) | 2008-10-08 | 2015-10-27 | Bioplus Life Sciences Pvt Ltda | "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo" |
| US20100099701A1 (en) | 2008-10-20 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Isoquinolinone modulators of 5-ht3 receptors |
| CN101444508B (zh) | 2008-12-29 | 2010-10-27 | 海南瑞基药物研究有限公司 | 一种注射用托烷司琼制剂及其制备方法 |
| EP2432437A4 (en) | 2009-05-21 | 2012-12-19 | Bionex Pharmaceuticals Llc | TWO- AND ONE-LAYER DOSAGE FORMS |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US9790109B2 (en) * | 2010-04-30 | 2017-10-17 | General Electric Company | Method for sanitizing an electrodeionization device |
| JP6250394B2 (ja) | 2010-08-19 | 2017-12-20 | バック・インスティテュート・フォー・リサーチ・オン・エイジング | 軽度の認知障害（ｍｃｉ）および関連障害の処置方法 |
| KR101368587B1 (ko) | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| EP2508174A1 (en) | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
| EP2814491A4 (en) | 2012-02-18 | 2015-08-26 | Buck Inst For Res On Aging | FORMULATIONS AND METHODS FOR TREATING OR PROPHYLAXIS OF PRE-MCI AND / OR PRE-ALZHEIMER ILLNESSES |
-
2011
- 2011-08-19 JP JP2013525003A patent/JP6250394B2/ja active Active
- 2011-08-19 DK DK11818848.1T patent/DK2605655T3/en active
- 2011-08-19 ES ES11818848T patent/ES2705027T3/es active Active
- 2011-08-19 US US13/213,960 patent/US10449177B2/en active Active
- 2011-08-19 BR BR112013003847A patent/BR112013003847A8/pt not_active IP Right Cessation
- 2011-08-19 MX MX2013001917A patent/MX353096B/es active IP Right Grant
- 2011-08-19 WO PCT/US2011/048472 patent/WO2012024616A1/en not_active Ceased
- 2011-08-19 EP EP11818848.1A patent/EP2605655B1/en active Active
- 2011-08-19 CA CA2808630A patent/CA2808630A1/en not_active Abandoned
- 2011-08-19 AU AU2011291506A patent/AU2011291506B2/en not_active Ceased
-
2016
- 2016-08-18 JP JP2016160482A patent/JP2016193944A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016193944A (ja) | 2016-11-17 |
| EP2605655A4 (en) | 2014-01-08 |
| CA2808630A1 (en) | 2012-02-23 |
| BR112013003847A2 (pt) | 2016-05-31 |
| JP2013534256A (ja) | 2013-09-02 |
| AU2011291506A1 (en) | 2013-03-14 |
| AU2011291506B2 (en) | 2016-07-28 |
| ES2705027T3 (es) | 2019-03-21 |
| EP2605655A1 (en) | 2013-06-26 |
| US10449177B2 (en) | 2019-10-22 |
| EP2605655B1 (en) | 2018-10-24 |
| JP6250394B2 (ja) | 2017-12-20 |
| BR112013003847A8 (pt) | 2017-12-26 |
| DK2605655T3 (en) | 2019-02-04 |
| WO2012024616A1 (en) | 2012-02-23 |
| MX2013001917A (es) | 2013-10-25 |
| US20120071468A1 (en) | 2012-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX353096B (es) | Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados. | |
| CY1122984T1 (el) | Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους | |
| EA201290919A1 (ru) | Индазольные соединения и их применение | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201992878A1 (ru) | Соединения для лечения болезни хантингтона | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
| MX358514B (es) | Compuestos para tratar la atrofia muscular espinal. | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| EA201590165A1 (ru) | Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения | |
| EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| EA201001847A1 (ru) | Соединения и композиции, применяемые для лечения малярии | |
| CL2014002062A1 (es) | Compuesto de moleculas pequeñas que inhiben cdk8 y cdk19, excluyendo cortistatina a y otros; formulacion farmceutica; un método para tratar a un mamifero que tiene una enfermedad relacionada con cdk1 como e. de alzheimer, otras demencias, amiloidosis, y un metodo para quimioproteger un paciente que padece cancer de ovario o mama, entre otros. | |
| NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| EA201691461A1 (ru) | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| EA201691590A1 (ru) | Бензимидазол-2-амины в качестве ингибиторов midhi | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| EA201200098A1 (ru) | Конденсированные имидазолы и содержащие их композиции, предназначенные для лечения паразитарных заболеваний, таких как, например, малярия | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| UY30220A1 (es) | Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo | |
| CL2008000202A1 (es) | Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |